ID: ALA4087567

Max Phase: Preclinical

Molecular Formula: C38H40ClN3O5

Molecular Weight: 654.21

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)C[C@H](NC(=O)c1cc(Cl)ccc1OCc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NC(C=O)Cc1ccccc1

Standard InChI:  InChI=1S/C38H40ClN3O5/c1-26(2)20-33(41-36(44)32-23-30(39)18-19-35(32)47-25-29-16-10-5-11-17-29)38(46)42-34(22-28-14-8-4-9-15-28)37(45)40-31(24-43)21-27-12-6-3-7-13-27/h3-19,23-24,26,31,33-34H,20-22,25H2,1-2H3,(H,40,45)(H,41,44)(H,42,46)/t31?,33-,34-/m0/s1

Standard InChI Key:  JXLRSGZBTMKOCD-MMNWNWMFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 654.21

Molecular Weight (Monoisotopic): 653.2656

AlogP: 5.72

#Rotatable Bonds: 16

Polar Surface Area: 113.60

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.04

CX Basic pKa:

CX LogP: 6.60

CX LogD: 6.60

Aromatic Rings: 4

Heavy Atoms: 47

QED Weighted: 0.13

Np Likeness Score: -0.28

References

1. Jorda R, Dušek J, Řezníčková E, Pauk K, Magar PP, Imramovský A, Kryštof V..  (2017)  Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.,  135  [PMID:28441582] [10.1016/j.ejmech.2017.04.027]

Source

Source(1):

• Scientific Literature